Prospective economic evaluation of phase III trial comparing irinotecan with infusional 5-FU in patients with advanced colorectal cancer

被引：0
|
作者：
Schmitt, C
Jolain, B
Van Cutsem, E
机构：
[1] UZ Gasthuisberg, Leuwen, Belgium
[2] Rhone Poulenc Rorer, Antony, France
[3] ARCOS, Issy Les Moulineaux, France
来源：
MEDICAL DECISION MAKING | 1998年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：484 / 484
页数：1
相关论文
共 50 条
  • [21] A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma
    Ducreux, M
    Rougier, P
    Pignon, JP
    Douillard, JY
    Seitz, JF
    Bugat, R
    Bosset, JF
    Merouche, Y
    Raoul, JL
    Ychou, M
    Adenis, A
    Berthault-Cvitkovic, F
    Luboinski, M
    ANNALS OF ONCOLOGY, 2002, 13 (08) : 1185 - 1191
  • [22] A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
    Glimelius, B.
    Sorbye, H.
    Balteskard, L.
    Bystrom, P.
    Pfeiffer, P.
    Tveit, K.
    Heikkila, R.
    Keldsen, N.
    Albertsson, M.
    Starkhammar, H.
    Garmo, H.
    Berglund, A.
    ANNALS OF ONCOLOGY, 2008, 19 (05) : 909 - 914
  • [23] THE COMBINATION OF BEVACIZUMAB AND INFUSIONAL 5-FU AND IRINOTECAN (FOLFIRI) IN ADVANCED, UNRESECTABLE COLORECTAL CANCER (CRC) PATIENTS IS SAFE AND FEASIBLE. RESULTS OF A SINGLE-CENTRE EXPERIENCE
    Diaz, R.
    Richart, P.
    de la Cueva, H.
    Huerta, A. A. Segura
    Corbellas, M.
    Garcia, J.
    Aparicio, J.
    Aparisi, F.
    Montalar, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 145 - 146
  • [24] Improved activity with irinotecan, oxaliplatin and infusional 5-FU/LV (FOLFOXIRI) compared with FOLFIRI in metastatic colorectal cancer (MCRC): results of a randomized Phase III trial by the Gruppo Oncologico Nord Ovest (GONO)
    Falcone, A.
    Brunetti, I. M.
    Benedetti, G.
    Evangelista, W.
    Picone, V.
    Vitello, S.
    Rosso, R.
    Granetto, C.
    Porcile, G.
    Masi, G.
    EJC SUPPLEMENTS, 2005, 3 (02): : 167 - 168
  • [25] Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas -: A multicenter phase II trial
    Feisthammel, Juergen
    Schoppmeyer, Konrad
    Moessner, Joachim
    Schulze, Manfred
    Caca, Karel
    Wiedmann, Marcus
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (03): : 319 - 324
  • [26] A PHASE III STUDY COMPARING LAROTAXEL TO 5-FU (CONTINUOUS INTRAVENOUS 5-FU OR CAPECITABINE) IN PATIENTS WITH ADVANCED PANCREATIC CANCER (APC) PREVIOUSLY TREATED WITH A GEMCITABINE CONTAINING REGIMEN
    Van Cutsem, E.
    Macarulla, T.
    Van Laethem, J.
    Couture, F.
    Peeters, M.
    Hoff, Gehn M.
    Roman, L.
    Lequesne, L.
    Charpentier, E.
    Conroy, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 13
  • [27] Phase II study of irinotecan and high dose infusional 5-FU and folinic acid (modified de Gramont) for first-line treatment of advanced or metastatic colorectal cancer
    Leonard, P
    Ledermann, JA
    James, R
    Hochhauser, D
    Seymour, M
    BRITISH JOURNAL OF CANCER, 2000, 83 : 19 - 19
  • [28] Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC)
    Zhang, Rong-xin
    Lin, Jun-zhong
    Lei, Jian
    Chen, Gong
    Li, Li-ren
    Lu, Zhen-hai
    Ding, Pei-rong
    Huang, Jiong-qiang
    Kong, Ling-heng
    Wang, Fu-long
    Li, Cong
    Jiang, Wu
    Ke, Chuan-feng
    Zhou, Wen-hao
    Fan, Wen-hua
    Liu, Qing
    Wan, De-sen
    Wu, Xiao-jun
    Pan, Zhi-zhong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (12) : 2581 - 2593
  • [29] Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC)
    Rong-xin Zhang
    Jun-zhong Lin
    Jian Lei
    Gong Chen
    Li-ren Li
    Zhen-hai Lu
    Pei-rong Ding
    Jiong-qiang Huang
    Ling-heng Kong
    Fu-long Wang
    Cong Li
    Wu Jiang
    Chuan-feng Ke
    Wen-hao Zhou
    Wen-hua Fan
    Qing Liu
    De-sen Wan
    Xiao-jun Wu
    Zhi-zhong Pan
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 2581 - 2593
  • [30] Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
    Van Cutsem, E.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Nippgen, J.
    Koehne, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345